Investor Relations :: SCYNEXIS, Inc. (SCYX)

Keep up to Date and Stay Informed

Sign up for email alerts to receive company updates including press releases, filings and special announcements straight to your inbox.

First Name

Last Name

Email Address

Contact Type:

Sign me up for:

Press Releases

Annual & Quarterly Reports

Current Reports

Insider Transactions

Proxy Information

All Filings

SCYNEXIS Completes Patient Enrollment Ahead of Schedule in the Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection)

Feb 13, 2020

View All News

Q3 2019

Quarter Ended Sep 30, 2019

PDF HTML

Earnings Release

PDF HTML

10-Q

ZIP XLS HTML

XBRL

SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas.

Investor Presentation

Download

Symbol

Nasdaq: SCYX

Price

Change

Daily Volume

52-week Low/High

Day Low/High

Investor Contact Information